About GlySure
GlySure is a company based in Abingdon (United Kingdom) founded in 2006. GlySure has raised $24.5 million across 2 funding rounds from investors including Amadeus Capital Partners, Delta Partners and Morningside China. The company has 41 employees as of March 31, 2018. GlySure operates in a competitive market with competitors including ZOLL AEDs, Attune Medical, InnAccel, ART Medical and Glucoset, among others.
- Headquarter Abingdon, United Kingdom
- Employees 41 as on 31 Mar, 2018
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Glysure Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.5 M (USD)
in 2 rounds
-
Latest Funding Round
$13.6 M (USD), Series C
Nov 28, 2012
-
Investors
Amadeus Capital Partners
& 3 more
-
Employee Count
41
as on Mar 31, 2018
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of GlySure
Unlock access to complete
Unlock access to complete
Funding Insights of GlySure
GlySure has successfully raised a total of $24.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $13.6 million completed in November 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GlySure
GlySure has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Amadeus Capital Partners, Delta Partners and Morningside China.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage deep technology investments are made by Amadeus Capital.
|
Locked | Locked | Locked | |
|
Early stage venture capital is provided to Irish startups.
|
Locked | Locked | Locked | |
|
VC and private equity investments are made in China-US companies.
|
Locked | Locked | Locked |
Investor details for GlySure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GlySure
Investment portfolio details for GlySure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GlySure
Detailed financials for GlySure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glysure Comparisons
Peer comparison for GlySure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GlySure
GlySure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZOLL AEDs, Attune Medical, InnAccel, ART Medical and Glucoset, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical devices and software for emergency care are developed.
|
|
| Locked | Locked | Locked |
Patient temperature is modulated via esophageal cooling devices.
|
|
| Locked | Locked | Locked |
Diversified medical devices are manufactured for critical and maternal care.
|
|
| Locked | Locked | Locked |
Safe enteral nourishment products for ICU patients are developed.
|
|
| Locked | Locked | Locked |
Continuous intravascular blood glucose monitoring devices are developed.
|
Detailed competitors of GlySure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glysure
Complete news archive for GlySure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GlySure
GlySure was founded in 2006 and raised its 1st funding round 6 years after it was founded.
GlySure is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
GlySure is a funded company, having raised a total of $24.5M across 2 funding rounds to date.
As of Mar 31, 2018, the latest employee count at GlySure is 41.
GlySure has developed a continuous intravascular (I.V) glucose monitoring system using a proprietary optical fluorescence sensor for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company claims to have demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patients stay in the ICU. Also, the company mentions that hospital TGC has shown in prospective outcomes trials to produce significant improvement in patient outcomes including 46 reduction in incidence of sepsis, 41 reduction in renal failure, and 34 reduction in mortality. As of December 2016, the Company is finalizing design of a clinical trial to support submission to the U.S. Food and Drug Administration (FDA).
GlySure's top competitors include ZOLL AEDs, Inspiration Healthcare and InnAccel.
GlySure has 4 investors. Key investors include Amadeus Capital Partners, Delta Partners, Morningside China, and Frank A Bonsal.